An international study carried out with involvement of the MedUni Vienna is giving hope to patients with advanced prostate cancer.
In just a few years’ time, Ipilumumab could be approved as a treatment for the world’s third-most common type of cancer.
The immunotherapeutic agent Ipilumumab has been shown to have a markedly positive effect in the treatment of patients who are resistant to conventional hormone treatments and chemotherapy. These are the words of a core statement from a study, recently published in the highly respected journal “The Lancet Oncology”, which was set up based on collaboration between the world’s leading centres for the research and treatment of prostate cancer.
The scientists investigated the extent to which immunotherapy with this agent is also suitable for the more common type of advanced prostate cancer. The medication is already being successfully used as immunotherapy for advanced melanoma – a comparatively rare type of cancer.
Read more . . .
The Latest on: Immunotherapy
[google_news title=”” keyword=”Immunotherapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Immunotherapy
- Supercharging immune cells to battle blood cancer: Advances in cancer immunotherapyon May 9, 2024 at 6:51 am
The research suggests that targeting CD300A could be a promising addition to immune checkpoint-based cancer immunotherapy. The ability to invigorate NK cell-based treatments against HMs offers new ...
- How new immunotherapy is helping treat advanced stage 4 melanomaon May 8, 2024 at 12:48 pm
Oncologists say the single-dose immunotherapy is currently approved for those with advanced stage 4 melanoma, who have not had success with other treatments. The process works by surgically removing a ...
- Biotech CEL-SCI gets FDA go-ahead to conduct investigational cancer immunotherapy studyon May 8, 2024 at 11:18 am
Listen to this article CEL-SCI Corporation, the Vienna, Virginia-based biotechnology company with operations in Baltimore, Wednesday received approval from the U.S. Food and Drug Administration to ...
- Can Vitamin D Improve Cancer Immunotherapy?on May 8, 2024 at 6:30 am
Your diet could impact your cancer treatment’s progress; a new preclinical study suggests more vitamin D could improve responses to checkpoint inhibitors.
- Study uncovers at least one cause of roadblocks to cancer immunotherapyon May 6, 2024 at 9:39 am
"These findings uncover new tactics that are employed by cancer to escape from immune cell attack and explain why some cancer immunotherapy strategies do not work well in the clinic," said Lieping ...
- Many Patients With Advanced MCC Not Receiving Immunotherapyon May 5, 2024 at 9:36 pm
Despite improved survival rates and guideline recommendations, many eligible patients with metastatic Merkel cell carcinoma are not receiving immunotherapy.
- Immunotherapy: A Beacon of Hope in Cancer Treatmenton May 4, 2024 at 2:25 pm
Cancer, a disease that has plagued humanity for centuries, has finally met its match in immunotherapy, a revolutionary treatment that harnesses the power of the immune system to combat this deadly ...
- Ketone supplement may boost immunotherapy against prostate canceron May 2, 2024 at 9:00 am
Researchers have found that adding a pre-ketone supplement to immunotherapy boosted its effectiveness against prostate cancer in mouse models.
- Breaking: AI Could Transform Cancer Treatment by Predicting Immunotherapy Successon April 30, 2024 at 8:27 am
In this article, we’ll explore a breakthrough development in the fight against cancer: how artificial intelligence (AI) is poised to predict immunotherapy success. This has the potential to ...
- Component of keto diet plus immunotherapy may reduce prostate canceron April 27, 2024 at 5:40 am
and Mary Jo Boler Collegiate Associate Professor in the Department of Biological Sciences, and collaborators tackled a problem oncologists have battled: Prostate cancer is resistant to a type of ...
via Bing News